Leopoldia comosa prevents metabolic disorders in rats with high-fat diet-induced obesity
- 385 Downloads
Obesity is the main feature of a complex illness known as metabolic syndrome. Anti-obesogenic therapies are often associated with side effects and represent a high cost in conventional pharmacological approaches. New strategies based on natural remedies are under continuous investigation. Leopoldia comosa (L.) Parl. (L. comosa) is a spontaneous plant with diuretic, anti-inflammatory and antioxidant properties. Recently, a hypoglycemic activity mediated by inhibition of carbohydrate digestion has been identified. The aim of this study was to evaluate the effects of a diet supplemented with L. comosa extracts on a rat model of diet-induced obesity.
Leopoldia comosa bulb extracts were obtained using a dynamic extractor. Phytochemical properties and in vitro determination of the antioxidant activity and of the inhibitory effects on lipase and pancreatic amylase were performed. Rats were fed (12 weeks) a standard diet, or a high-fat diet (HFD), or an HFD plus L. comosa (20 or 60 mg/die) extracts. The metabolic and anthropometric parameters were recorded.
Results indicated that L. comosa inhibited lipase and pancreatic amylase activities. In vivo data showed that the supplementation with both doses of L. comosa extracts counteracted the HFD-dependent effects. It reduced body weight, abdominal obesity and dyslipidemia, and improved glucose tolerance with a reduction of lipidic tissue hypertrophy and liver steatosis, as compared to HFD-fed rat. In liver, L. comosa reduced protein expression levels of PEPCK and G6Pase.
We suggest that L. comosa extracts prevent obesity-dependent metabolic disorders. This paves the way for their therapeutic application as a natural anti-obesity drug.
KeywordsLeopoldia comosa (L.) Parl. Obesity Metabolism Homoisoflavanones Pancreatic lipase Antioxidant activity
This research was supported by “Dottorato di Ricerca in Medicina Traslazionale” (C.T.), “Dottorato di Ricerca in Scienze della Vita” (S.F., R.C., G.M.C., D.A., R.M., T.A) and MIUR of Italy (ex 60%).
Compliance with ethical standards
Conflict of interest
The authors have nothing to disclose.
- 4.Sniderman A, Cainflone K (1995) Metabolic disruptions in the adipocyte–hepatocyte fatty acid axis as causes of HyperapoB. Int J Obesity 19:S27–S33Google Scholar
- 7.de Freitas Junior LM, de Almeida EB Jr (2017) Medicinal plants for the treatment of obesity: ethnopharmacological approach and chemical and biological studies. Am J Transl Res 9(5):2050–2064Google Scholar
- 23.Kim JH, Kim OK, Yoon HG, Park J, You Y, Kim K, Lee YH, Choi KC, Lee J, Jun W (2016) Anti-obesity effect of extract from fermented Curcuma longa L. through regulation of adipogenesis and lipolysis pathway in high-fat diet-induced obese rats. Food Nutr Res 60:30428. https://doi.org/10.3402/fnr.v60.30428 CrossRefGoogle Scholar
- 33.Marrelli M, Loizzo MR, Nicoletti M, Menechini F, Conforti F (2014) In vitro investigation of the potential health benefits of wild Mediterranean dietary plants as anti-obesity agents with α-amylase and pancreatic lipase inhibitory activities. J Sci Food Agric 94(11):2217–2224. https://doi.org/10.1002/jsfa.6544 CrossRefGoogle Scholar
- 36.Eichler HG, Korn A, Gasic S, Prison W, Businger J (1984) The effect of new specific α-amylase inhibitor on post-prandial glucose and insulin excursions in normal subjects and Type 2 (non-insulin dependent) diabetic patients. Diabetologia 26(4):278–281. https://doi.org/10.1007/BF00283650 CrossRefGoogle Scholar
- 37.Tarling CA, Woods K, Zhang R, Brastianos HC, Brayer GD, Andersen RJ, Withers SG (2008) The search for novel human pancreatic α-amylase inhibitors: high-throughput screening of terrestrial and marine natural product extracts. Chem Bio Chem 9:433–438. https://doi.org/10.1002/cbic.200700470 CrossRefGoogle Scholar